Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-05-27 17:57:37 ET · period of report 2026-05-22 · accession 0001610717-26-000164 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-05-27 17:57 | 2026-05-22+ | TXG | Saxonov Serge | CEO, Dir | S - Sale | $24.54 | -28.9K | 1.14M | -2% | -$709.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-05-22 | S | D | 18,175 | $24.44 | 1,149,098 | D | — | — | (F1) The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
| 2 | Common | Class A Common Stock | 2026-05-26 | S | D | 10,718 | $24.71 | 1,138,380 | D | — | — | (F2) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |